Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →In a retrospective case-control study of 32 children with ALL and 30 matched healthy controls, serum 8-OHdG was elevated before treatment, decreased after chemotherapy, and was similar to control levels after treatment.
The study provides evidence that serum 8-OHdG tracks with the treated versus pretreatment state in pediatric ALL; it remains an inference, requiring prospective validation against remission, relapse, toxicity, and survival outcomes, that 8-OHdG could serve as a treatment-response or oxidative-injury biomarker.
This systematic review and qualitative meta-synthesis of 18 studies reports that eating during cancer treatment is an embodied, emotional, and social struggle for AYAs, while identifying gaps in support and offering 13 evidence-informed care recommendations.
The synthesis supports individualized nutritional, dietetic, family, and psychosocial support as relevant care targets; it is reasonable to hypothesize that tailored interventions addressing these domains could improve eating-related quality of life, but intervention efficacy, safety, and clinical outcomes were not tested in the supplied record.
This review describes retinoblastoma genetics and the immune-privileged tumor microenvironment, highlighting reported associations of checkpoint molecules with adverse disease features and discussing checkpoint-directed and cellular therapies as potential strategies.
The supplied abstract reports that increased immune-checkpoint levels have been associated with poor prognosis, aggressiveness, and chemotherapy resistance; it infers—but does not demonstrate—that targeting PD-1/PD-L1, CTLA-4, B7-H3, LAG-3, TIM-3, TIGIT, or related immune pathways could improve retinoblastoma treatment.
This preprint reports a single-cell multiomic variant-to-function map of inherited childhood B-ALL risk, identifies 34 high-confidence susceptibility genes, and functionally validates a risk allele associated with selective ELK3 upregulation.
The evidence links inherited regulatory variation, including an ELK3-upregulating allele, to B-cell progenitor programs associated with B-ALL predisposition; it remains an inference that targeting ELK3-related pathways or these regulatory programs could enable prevention, risk-adapted surveillance, or therapy.
This report describes a 16-year-old male with refractory multifocal chronic non-bacterial osteitis who achieved clinical and MRI remission within six months of starting tofacitinib after an inadequate response to NSAIDs.
The case provides preliminary evidence that tofacitinib may suppress refractory CNO manifestations; it is an inference, not established by this report, that JAK-pathway inhibition is responsible or that the response would generalize to other pediatric patients.
In a Japanese registry cohort of 14,430 day-100 survivors after first allogeneic HSCT for hematologic malignancies, a stacked ensemble model modestly improved prediction of chronic GVHD, non-relapse mortality, and all-cause mortality, with performance increasing when early acute GVHD information was added.
The evidence supports early acute GVHD, particularly grade III–IV disease, as a predictor of later mortality outcomes; it is reasonable but unproven to hypothesize that dynamically updated risk estimates could guide intensified monitoring or risk-adapted interventions, including in pediatric patients.
In an institutional cohort of 47 children and young adults with seizure-associated supratentorial gangliogliomas, volumetric resection of at least 84% was associated with greater odds of Engel Class I seizure freedom at 12 months.
The study provides observational evidence that greater volumetric extent of resection, particularly ≥84%, predicts short-term seizure freedom; it remains an inference requiring external validation that this threshold could guide surgical planning when gross total resection is unsafe or infeasible.
In a Danish nationwide registry cohort of 3,075 children diagnosed with cancer before age 18 during 2014–2024, auditory late effects were recorded in 5.7%, with higher risk reported among younger patients, those with malignant neoplasms, and those receiving high-dose chemotherapy at younger ages.
The study provides observational evidence supporting risk-stratified auditory surveillance in childhood cancer survivors; it is reasonable but untested to infer that earlier detection and intervention could reduce developmental or quality-of-life consequences.
In a single-center retrospective cohort of 170 surgically treated supratentorial intraventricular tumours, including 31 children, tumour grade and surgical approach predicted gross total resection, while recurrence and 30-day mortality were significantly worse in children and high-grade tumours.
The evidence supports using tumour grade, operative approach, and presenting hydrocephalus for risk stratification and perioperative planning; it remains an inference, requiring prospective and pediatric-specific validation, that approach selection or anticipatory shunt planning could improve outcomes.
In a prospective single-centre assessment involving 50 children and adolescents receiving their first molecular radiotherapy cycle, caregivers reported unmet psychosocial, financial, practical, and treatment-specific needs, particularly around travel, isolation, family separation, and limited support access.
The study provides observational evidence of recurring caregiver needs; it supports the inference that structured needs assessment, multidisciplinary coordination, virtual peer support, educational continuity, and integration of local services could reduce family burden, but these interventions and their effects on patient outcomes were not tested.
This multicenter retrospective case-control study found that 18 patients recovered from apparently chronic arginine vasopressin deficiency after a median of 6.3 years and identified clinical associations that may support periodic reassessment of desmopressin need, while separately presenting three pediatric recovery cases.
The evidence shows that late recovery from chronic AVP deficiency can occur and is associated with lower desmopressin doses and absence of some concurrent pituitary deficiencies; it is reasonable—but not proven by this retrospective study—to hypothesize that structured reassessment could identify selected pediatric tumor survivors who no longer require desmopressin, potentially reducing unnecessary treatment and toxicity risk.
In a nationwide Brazilian registry cohort of 102,430 cancer cases diagnosed at ages 0–19 years from 2000–2023, 24.7% experienced early death, which was associated with tumor type and multiple demographic, regional, referral, treatment, and missing-data variables.
The study provides observational evidence that early mortality clusters with social, regional, clinical, and care-related factors; it supports the inference that targeted referral, data-quality, access, and supportive-care interventions might reduce early deaths, but it does not test such interventions or establish that treatment exposures causally increase or decrease mortality.
